John Libbey Eurotext



Transfusion sanguine en hématologie : bonnes pratiques et aide au conseil transfusionnel Volume 23, numéro 1, Janvier-Février 2017

  • [1] Haute Autorité de Santé - Transfusions de globules rouges homologues : produits, indications, alternatives [Internet].
  • [2] Vamvakas E.C. The abandoned controversy surrounding universal white blood cell reduction. Blood Transfus. 2014;12:143-145.
  • [3] Andreu G., Vasse J., Sandid I., Semana G. Use of random versus apheresis platelet concentrates. Transfus Clin Biol. 2007;14:514-521.
  • [4]
  • [5] Wu Y., Zou S., Cable R. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion (Paris). 2010;50:776-786.
  • [6]
  • [7] Mertes P.-M., Boudjedir K. Transfusion and allergy. Transfus Clin Biol. 2013;20:239-242.
  • [8] Rosencher N., Ozier Y., Souied F., Lienhart A., Samama C.-M. How can we explain the gap between randomised studies and “real life” practice in postoperative transfusion triggers? Do we need to change recommended thresholds for transfusion? Eur J Anaesthesiol. 2012;29:460-461.
  • [9] Szczepiorkowski Z.M., Dunbar N.M. Transfusion guidelines: when to transfuse. ASH Educ Program Book. 2013;2013:638-644.
  • [10] Carson J.L., Stanworth S.J., Roubinian N. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2016;10:CD002042.
  • [11] Wandt H., Schaefer-Eckart K., Wendelin K. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012;380:1309-1316.
  • [12] Simancas-Racines D., Osorio D., Martí-Carvajal A.J., Arevalo-Rodriguez I. Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion. Cochrane Database Syst Rev. 2015;12:CD009745.
  • [13] Rapport d’activité Hémovigilance 2015.
  • [14] Delaney M., Wendel S., Bercovitz R.S. Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016;388:2825-2826.
  • [15] Porter J.B., de Witte T., Cappellini M.D., Gattermann N. New insights into transfusion-related iron toxicity: Implications for the oncologist. Crit Rev Oncol Hematol. 2016;99:261-271.
  • [16] Stanworth S.J., Navarrete C., Estcourt L., Marsh J. Platelet refractoriness--practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015;171:297-305.
  • [17] Tardivel R., Garban F., Gimeno L. Caractéristiques des concentrés de plaquettes (CP) transfusés lors du protocole EFFIPAP. Transfus Clin Biol. 2015;22:206.
  • [18] Ypma P.F., van der Meer P.F., Heddle N.M. PREPAReS Study Group, A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial. BMJ Open. 2016;6:e010156.
  • [19] Tseng E., Spradbrow J., Cao X., Callum J., Lin Y. An order set and checklist improve physician transfusion ordering practices to mitigate the risk of transfusion-associated circulatory overload. Transfus Med. 2016;26:104-110.